Desmopressin

Pharmacologic Category

Antihemophilic Agent; Hemostatic Agent; Hormone, Posterior Pituitary; Vasopressin Analog, Synthetic

Dosing: Adult

Diabetes insipidus: Note: Fluid restriction should be observed. Dosing should be individualized to response.

IV, SubQ: US labeling: 2 to 4 mcg daily (0.5 to 1 mL) in 2 divided doses or one-tenth (1/10) of the maintenance intranasal dose. Fluid restriction should be observed.

IM, IV, SubQ: Canadian labeling (DDAVP Injection only): 1 to 4 mcg (0.25 to 1 mL) once daily or one-tenth (1/10) of the maintenance intranasal dose. Fluid restriction should be observed.

Intranasal (100 mcg/mL nasal solution): Usual dose range: 10 to 40 mcg daily (0.1 to 0.4 mL) as a single dose or divided 2 to 3 times daily; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover. Most adults require 10 mcg (0.1 mL) twice daily. Note: The nasal spray pump can only deliver doses of 10 mcg (0.1 mL) or multiples of 10 mcg (0.1 mL); if doses other than this are needed, the rhinal tube delivery system is preferred. Fluid restriction should be observed.

Conversion from injection to intranasal: Administer 10 times the amount of desmopressin acetate, rounded down to the nearest 10 mcg.

Conversion from oral to intranasal: Individual dose titration is required (intranasal desmopressin ~10- to 40-fold more potent than oral desmopressin).

Oral: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1 to 1.2 mg divided 2 to 3 times daily). Fluid restriction should be observed.

Sublingual formulation [Canadian product]: DDAVP Melt: Initial: 60 mcg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 120 to 720 mcg equally divided 2 or 3 times daily. Fluid restriction should be observed.

Hemophilia A and von Willebrand disease (type 1):

IV: 0.3 mcg/kg by slow infusion; may repeat dose if needed (based on clinical response and laboratory results); if used preoperatively, administer 30 minutes before procedure. A maximum IV dose of 20 mcg has been recommended (DDAVP injection Canadian product labeling).

SubQ: Octostim [Canadian product]: 0.3 mcg/kg; may repeat dose if needed (based on clinical response and laboratory results); if used preoperatively, administer 30 minutes before procedure

Intranasal (using high concentration spray [1.5 mg/mL]): <50 kg: 150 mcg (1 spray in a single nostril); ≥50 kg: 300 mcg (1 spray each nostril); repeat use is determined by the patient's clinical condition and laboratory work. If using preoperatively, administer 2 hours before surgery.

Hyponatremia (adjunct to hypertonic saline infusion to prevent overly rapid sodium correction) (off-label use): Note: Desmopressin should only be used as adjunctive therapy to hypertonic saline in patients with severe hyponatremia (<120 mEq/L) due to rapidly reversible causes (eg, hypovolemia) who are likely to develop water diuresis during the course of therapy or in those who are at high risk of osmotic demyelination syndrome. In these situations, desmopressin helps make serum sodium correction more predictable during hypertonic saline administration. Adjunctive desmopressin use is not recommended in patients whose cause of hyponatremia is not rapidly reversible (eg, edema due to heart failure or cirrhosis) or in patients with chronic syndrome of inappropriate antidiuretic hormone secretion (Sterns 2018).

IV, SubQ: 1 to 2 mcg every 6 to 8 hours for 24 to 48 hours or until serum sodium increases to ≥125 mEq/L (Sood 2013; Sterns 2018). Free water intake should be restricted during treatment. Experts recommend initiating desmopressin proactively (ie, at the beginning of treatment for hyponatremia) (Sterns 2018).

Intracranial hemorrhage associated with certain antiplatelet agents (aspirin, clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor) (off-label use): IV: 0.4 mcg/kg once (NCS/SCCM [Frontera 2016]).

Nocturia:

Intranasal: Noctiva:

Not at risk for hyponatremia: 1.66 mcg in either nostril ~30 minutes before bedtime.

At risk for hyponatremia: Initial: 0.83 mcg in either nostril ~30 minutes before bedtime. After ≥7 days, may increase to 1.66 mcg if needed (provided the serum sodium is within the normal range during treatment with the 0.83 mcg dose). Note: The 0.83 mcg dose did not meet all prespecified efficacy endpoints in clinical trials but may have a lower risk of hyponatremia.

Sublingual: Nocdurna: Note: Dosage expressed as desmopressin acetate. Desmopressin acetate 27.7 mcg is equivalent to desmopressin (base) 25 mcg.

Females: 27.7 mcg once daily one hour before bedtime

Males: 55.3 mcg once daily one hour before bedtime

Primary nocturnal enuresis:

Oral: Initial: 0.2 mg at bedtime; dose may be titrated up to 0.6 mg to achieve desired response.

Sublingual formulation [Canadian product]: DDAVP Melt: Initial: 120 mcg administered 1 hour before bedtime; if bedwetting occurs after 3 days increase dose by 120 mcg/day. Dose may be further titrated up to a maximum of 360 mcg/day to achieve desired response. Treatment period is up to 3 months and then reassess with 1 week off treatment; if additional therapy is necessary, resume at same dosage prior to discontinuation.

Uremic bleeding: Octostim [Canadian product]: IV: 0.3 mcg/kg over 20 to 30 minutes (maximum dose: 20 mcg)

Uremic bleeding associated with acute or chronic renal failure (off-label use in US): IV: 0.4 mcg/kg over 10 minutes (Watson 1984)

Prevention of surgical bleeding in patients with uremia (off-label use in US): IV: 0.3 mcg/kg over 30 minutes (Mannucci 1983)

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Nocturia: Avoid use (Beers Criteria [AGS 2019]).

Dosing: Renal Impairment: Adult

CrCl ≥50 mL/minute (DDAVP) or eGFR ≥50 mL/minute/1.73 m2 (Nocdurna, Noctiva): No dosage adjustment necessary.

CrCl <50 mL/minute (DDAVP) or eGFR <50 mL/minute/1.73 m2 (Nocdurna, Noctiva): Use is contraindicated according to the manufacturer's labeling (except 1.5 mg/mL nasal spray); however, has been used in acute and chronic renal failure patients experiencing uremic bleeding or for prevention of surgical bleeding (off-label uses in US) (Mannucci 1983; Watson 1984).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

Note: Dosing presented is in mcg, mg, and mL (dependent upon product formulation); use extra precaution to verify product formulation and dosing units. Intranasal dosage forms have unique concentrations and indications for use and should not be used interchangeably; use in pediatric patients is contraindicated for some products (eg, Noctiva); consult product labeling.

Diabetes insipidus: Note: Fluid restriction should be observed in these patients; younger patients are more susceptible to plasma osmolality shifts and possible hyponatremia. Dosing should be individualized to response.

Oral: Children ≥4 years and Adolescents: Initial: 0.05 mg twice daily; titrate to desired response; optimal daily dose range: 0.1 to 0.8 mg/day in 2 to 3 divided doses; reported daily dose range: 0.1 to 1.2 mg/day

Intranasal:

DDAVP nasal spray (10 mcg/spray): Note: The nasal spray pump can only deliver fixed doses in 10 mcg (0.1 mL) increments; if doses other than this are needed, the rhinal tube delivery system is preferred.

Children ≥4 years and Adolescents: Initial: 10 mcg once daily into 1 nostril, may titrate dose up to 30 mcg/day in 1 to 2 divided doses; if administered twice daily, adjust morning and evening doses separately to provide for an adequate diurnal rhythm of urine output.

Rhinal tube (100 mcg/mL nasal solution):

Infants ≥3 months and Children: Initial: 5 mcg/day in 1 to 2 divided doses; usual range: 5 to 30 mcg/day in 1 to 2 divided doses; if administered twice daily, adjust morning and evening doses separately to provide for an adequate diurnal rhythm of urine output.

Adolescents: Usual range: 5 to 40 mcg/day in 1 to 3 divided doses; usual adult dose is 20 mcg/day in 2 divided doses; adjust morning and evening doses separately to provide for an adequate diurnal rhythm of urine output.

Parenteral:

Infants and Children <12 years: IV, SubQ: No definitive dosing available. Adult dosing should not be used in this age group; adverse events such as hyponatremia-induced seizures may occur. Dose should be reduced. Some have suggested an initial dosage range of 0.1 to 1 mcg in 1 or 2 divided doses (Cheetham 2002). Initiate at low dose and increase as necessary. Closely monitor serum sodium levels and urine output; fluid restriction is recommended.

Children ≥12 years and Adolescents: IV, SubQ: 2 to 4 mcg/day in 2 divided doses or one-tenth (1/10) of the maintenance intranasal dose; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover

Sublingual: Canadian labeling: DDAVP Melt [Canadian product]: Children and Adolescents: Sublingual: Initial: 60 mcg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance dose: 120 to 720 mcg in divided doses 2 to 3 times daily; divide daily doses so that the evening dose is 2 times higher than the morning or afternoon dose to ensure adequate antidiuresis during the night; fluid restriction should be observed.

Hemophilia A and von Willebrand disease (type 1; mild to moderate): Note: Adverse events such as hyponatremia-induced seizures have been reported especially in young children with IV use (Das 2005; Molnár 2005; Smith 1989; Thumfart 2005; Weinstein 1989). Fluid restriction and careful monitoring of serum sodium levels and urine output are necessary.

IV: Infants ≥3 months, Children, and Adolescents: 0.3 mcg/kg; if used preoperatively administer 30 minutes before procedure; may repeat dose if needed

Intranasal: High concentration spray 1.5 mg/mL: Infants ≥11 months, Children, and Adolescents:

<50 kg: 150 mcg (1 spray)

≥50 kg: 300 mcg (1 spray in each nostril)

Repeat use is determined by the patient's clinical condition and laboratory work; if using preoperatively, administer 2 hours before surgery

Subcutaneous: Canadian labeling: Octostim [Canadian product]: Infants ≥3 months, Children, and Adolescents: SubQ: 0.3 mcg/kg; if used preoperatively administer 30 minutes before procedure

Nocturnal enuresis: Note: Intranasal formulations are not recommended for nocturnal enuresis treatment.

Oral:

Children ≥6 years and Adolescents: Initial: 0.2 mg once before bedtime; titrate as needed to a maximum of 0.6 mg/day; fluid intake should be limited to a minimum from 1 hour before desmopressin administration until the next morning, or at least 8 hours after administration

Canadian labeling: Children ≥5 years and Adolescents: Initial: 0.2 mg once before bedtime; may titrate by 0.2 mg/day every 3 days as needed to a maximum dose of 0.6 mg/day; fluid intake should be limited to a minimum from 1 hour before desmopressin administration until the next morning, or at least 8 hours after administration. Treatment period is up to 3 months and then reassess with 1 week off treatment; if additional therapy is necessary, resume at same dosage prior to discontinuation.

Sublingual: Canadian labeling: DDAVP Melt [Canadian product]: Children ≥5 years and Adolescents: Sublingual: Initial: 120 mcg administered 1 hour before bedtime; may titrate by 120 mcg/day every 3 days as necessary to a maximum dose of 360 mcg/day to achieve desired response. Treatment period is up to 3 months and then reassess with 1 week off treatment; if additional therapy is necessary, resume at same dosage prior to discontinuation.

Dosing: Renal Impairment: Pediatric

CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.

CrCl <50 mL/minute: Use is contraindicated according to the manufacturer (except 1.5 mg/mL nasal spray); however, has been used in acute and chronic renal failure adult patients experiencing uremic bleeding or for prevention of surgical bleeding (Mannucci 1983; Watson 1984).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Calculations

• Creatinine Clearance by Cockcroft-Gault
• Creatinine Clearance by Cockcroft-Gault (SI units)
• Creatinine Clearance by Cockcroft-Gault with IBW
• Creatinine Clearance by Cockcroft-Gault with IBW (SI units)
• Creatinine Clearance by Jelliffe
• Creatinine Clearance by Sanaka
• Glomerular Filtration Rate by Abbreviated MDRD
• Glomerular Filtration Rate by Abbreviated MDRD (SI units)
• Glomerular Filtration Rate by MDRD
• Glomerular Filtration Rate by MDRD (IDMS-Traceable SCr)
• Glomerular Filtration Rate by MDRD (SI units)
• Glomerular Filtration Rate by Schwartz
• Glomerular Filtration Rate Estimate in African Americans by AASK Equation

Use: Labeled Indications

Injection:

Diabetes insipidus: Antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus; management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Limitations of use: Desmopressin is ineffective for the treatment of nephrogenic diabetes insipidus.

Hemophilia A: For use in patients with hemophilia A with factor VIII coagulant activity levels >5% to maintain hemostasis during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure and to also stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, or mucosal bleeding.

Limitations of use: Not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels ≤5%, for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin with careful monitoring in patients with factor VIII levels between 2% and 5%.

Von Willebrand disease (type 1): For use in patients with mild to moderate classic von Willebrand disease (type 1) with factor VIII coagulant activity levels >5% to maintain hemostasis during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure and to stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, or mucosal bleeding.

Limitations of use: Patients with von Willebrand disease who are least likely to respond are those with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels <1%; other patients may respond (variable) depending on the type of molecular defect they have. Check bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen during administration of desmopressin to ensure that adequate levels are being achieved. Not indicated for the treatment of severe classic von Willebrand disease (type I) or when there is evidence of an abnormal molecular form of factor VIII antigen.

Uremic bleeding (Octostim [Canadian product]): Prevention or treatment of bleeding in patients with uremia.

Intranasal:

Diabetes insipidus:

DDAVP Nasal Spray: Antidiuretic replacement therapy in the management of central diabetes insipidus in adults and children ≥4 years.

DDAVP Rhinal tube: Antidiuretic replacement therapy in the management of central diabetes insipidus; management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Limitation of use: Treatment of nephrogenic diabetes insipidus or primary nocturnal enuresis.

Hemophilia A (Stimate; Octostim [Canadian product]): For use in patients with hemophilia A with factor VIII coagulant activity levels >5% and to stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, or mucosal bleeding.

Limitations of use: Not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels ≤5%, for the treatment of hemophilia B, or in patients who have factor VIII antibodies.

Nocturia (Noctiva): Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Limitations of use: Has not been studied in patients <50 years of age.

von Willebrand disease (type 1) (Stimate; Octostim [Canadian product]): For use in patients with mild to moderate classic von Willebrand disease (type 1) with factor VIII coagulant activity levels >5% and to stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, mucosal bleeding, or menorrhagia.

Limitations of use: Not indicated for the treatment of severe classic von Willebrand disease (type 1) or when there is evidence of an abnormal molecular form of factor VIII antigen.

Oral:

Diabetes insipidus: Antidiuretic replacement therapy in the management of central diabetes insipidus; management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Limitation of use: Desmopressin is ineffective for the treatment of nephrogenic diabetes insipidus.

Nocturia (Nocdurna): Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Primary nocturnal enuresis: Management of primary nocturnal enuresis, either alone or as an adjunct to behavioral conditioning or other nonpharmacologic intervention.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Hyponatremia (adjunct to hypertonic saline infusion to prevent overly rapid sodium correction)Level of Evidence [C]

Data from a limited number of patients (case series) with severe hyponatremia (serum sodium <120 mEq/L) suggest that treatment with desmopressin as an adjunct to hypertonic saline may be beneficial for preventing overly rapid correction of hyponatremia Ref.

Note: Hyponatremia is listed as a contraindication for use of desmopressin in some instances. Use only in consultation with clinicians experienced in the management of hyponatremia. Dosing: Adult outlines appropriate patient selection.

Intracranial hemorrhage associated with certain antiplatelet agentsLevel of Evidence [G]

Based on the Neurocritical Care Society and the Society of Critical Care Medicine guideline for reversal of antithrombotics in intracranial hemorrhage, desmopressin intravenous is suggested and may be considered in intracranial hemorrhage associated with certain antiplatelet agents (eg, aspirin, clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor).

Surgical bleeding in patients with uremia (prevention)Level of Evidence [A]

Data from a randomized, double-blind cross-over trial in patients with uremia, hemorrhagic tendencies, and prolonged bleeding times who were to undergo major surgery or renal biopsy supports the use of IV desmopressin for the prevention of bleeding in these patients Ref.

Uremic bleeding associated with acute or chronic renal failureLevel of Evidence [C]

Data from a limited number of patients (case series) who were experiencing hemorrhage in the setting of renal insufficiency suggests that IV desmopressin may be beneficial for the treatment of this condition Ref. Additional data may be necessary to further define the role of desmopressin in the management of this condition. With the use of recombinant erythropoietin in patients with chronic renal failure, uremic bleeding is much less common than it was previously Ref.

Level of Evidence Definitions

Level of Evidence Scale

Comparative Efficacy

• DESMOPRESSIN ACETATE NASAL SPRAY

Clinical Practice Guidelines

Benign Prostatic Hyperplasia:

CUA, “Guideline on Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (MLUTS/BPH),” 2018

Bleeding Disorders:

Royal College of Obstetricians and Gynaecologists, “Management of Inherited Bleeding Disorders in Pregnancy,” April 2017

Hypopituitarism:

Endocrine Society, “Hormonal Replacement in Hypopituitarism in Adults,” 2016

Life-Threatening Hemorrhage:

NCS/SCCM, “Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage,” 2016

Administration: IM

Canadian labeling (DDAVP Injection only; IM route not in US labeling): Central diabetes insipidus: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.

Administration: IV

IV push: Central diabetes insipidus: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.

IV infusion:

Hemophilia A, von Willebrand disease (type 1), and prevention of surgical bleeding in patients with uremia (off-label) (Mannucci 1983): Infuse over 15 to 30 minutes

Acute uremic bleeding (off-label) (Watson 1984): May infuse over 10 minutes

Uremic bleeding: Octostim [Canadian product]: Bleeding time should be normalized by administering a test dose once bleeding disorder is diagnosed or at least 72 hours prior to surgical procedures. Infuse over 20 to 30 minutes. When used pre-operatively administer 30 minutes prior to procedure.

Administration: Injectable Detail

pH: 4 (4 mcg/mL solution)

Administration: Oral

Oral, tablet:

May administer with or without food. Food may reduce/delay absorption although does not affect antidiuretic activity (Rittig 1998).

Diabetes insipidus: Fluid restriction should be observed.

Primary nocturnal enuresis: Minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).

Sublingual:

Nocturia (Nocdurna): Tablet should be kept under the tongue until completely dissolved. Administer 1 hour prior to bedtime. Fluid intake should be limited 1 hour prior to dose until at least 8 hours after administration.

Primary nocturnal enuresis (DDAVP Melt [Canadian product]): Tablet should be kept under the tongue until completely dissolved. Fluid restriction should be observed. Minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).

Administration: Subcutaneous

Central diabetes insipidus: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.

Administration: Intranasal

Ensure that nasal passages are intact, clean, and free of obstruction prior to administration.

DDAVP: Nasal pump spray: Delivers 0.1 mL (10 mcg); for doses <10 mcg or for other doses which are not multiples, use rhinal tube. DDAVP Nasal spray delivers fifty 10 mcg doses. For 10 mcg dose, administer in one nostril. Any solution remaining after 50 doses should be discarded. Pump must be primed prior to first use by pressing down on pump 4 times; if pump not used for ≥1 week, re-prime by pressing down on pump once.

DDAVP Rhinal tube: Insert top of dropper into tube (arrow marked end) in downward position. Squeeze dropper until solution reaches desired calibration mark. Disconnect dropper. Grasp the tube 3/4 inch from the end and insert tube into nostril until the fingertips reach the nostril. Place opposite end of tube into the mouth (holding breath). Tilt head back and blow with a strong, short puff into the nostril. Reseal dropper after use.

Noctiva: Do not shake. Prime before using for the first time by pumping 5 actuations into the air away from the face. Re-prime by pumping 2 actuations into the air if the product has not been used for more than 3 days. Note: 2 sprays of 0.83 mcg/0.1 mL are not interchangeable with 1 spray of 1.66 mcg/0.1 mL; do not administer 2 sprays of the 0.83 mcg/0.1 mL product.

Octostim [Canadian product]: Gently blow nose to clear nasal passages. Prior to initial use, prime the pump by pressing down at least 5 times until an even spray appears. Spray is then ready for use. Dip tube inside bottle must always be submerged in the liquid when spraying. Tilt head back slightly and insert nasal applicator into one nostril. Hold breath as dose is administered. Repeat in opposite nostril if an additional spray is required. If used preoperatively, administer 2 hours prior to procedure. If spray pump is not used for 48 hours it must be primed again by pressing down a couple of times until an even spray appears. Pump will only deliver 150 mcg dose(s); if a different dose is needed, use the injection. Note: A test dose to measure response is recommended prior to initiating therapy.

Stimate: Press pump down 4 times to prime prior to initial use. Once ready, tilt pump, place nozzle tip in nostril, then spray. If pump has not been used for one week it must be primed again by pressing down once or until a fine mist is present. Discard after 25 sprays (excluding priming sprays). Note: A test dose to measure response is recommended prior to initiating therapy.

Administration: Pediatric

Intranasal: Ensure that nasal passages are intact, clean, and free of obstruction prior to administration.

DDAVP (100 mcg/mL): Nasal pump spray: Delivers 0.1 mL (10 mcg); for doses <10 mcg or for other doses which are not multiples, use rhinal tube. DDAVP nasal spray delivers fifty 10 mcg doses in the 5 mL bottle. For 10 mcg dose, administer in one nostril. Any solution remaining after 50 doses should be discarded. Pump must be primed prior to first use by pressing down on pump 4 times; if pump not used for ≥1 week, re-prime by pressing down on pump once.

DDAVP Rhinal tube (100 mcg/mL): Insert top of dropper into tube (arrow marked end) in downward position. Squeeze dropper until solution reaches desired calibration mark. Disconnect dropper. Grasp the tube 3/4-inch from the end and insert tube into nostril until the fingertips reach the nostril. Place opposite end of tube into the mouth (holding breath). Tilt head back and blow with a strong, short puff into the nostril (for very young patients, an adult should blow solution into the child's nose). Reseal dropper after use.

Stimate (1.5 mg/mL): Nasal pump spray: Delivers 0.1 mL (150 mcg); for doses <150 mcg, injection is recommended. Stimate nasal spray delivers twenty-five 150 mcg doses. For 150 mcg dose, administer in one nostril. Any solution remaining after 25 doses should be discarded. Pump must be primed prior to first use or if not used for ≥1 week.

Octostim (1.5 mg/mL) [Canadian product]: Gently blow nose to clear nasal passages. Prior to initial use, prime the pump by pumping at least 5 actuations into the air until an even spray appears. Dip tube inside bottle must always be submerged in the liquid when spraying. Tilt head back slightly and insert nasal applicator into one nostril. Hold breath as dose is administered. Repeat in opposite nostril if an additional spray is required. If spray pump is not used for 48 hours it must be primed again by pressing down a couple of times until an even spray appears. Pump will only deliver doses in increments of 150 mcg; if a different dose is needed, use the injection.

Oral: Tablets: May administer with or without food. In adults, food may reduce/delay absorption although does not affect antidiuretic activity (Rittig 1998).

Diabetes insipidus: Fluid restriction should be observed.

Primary nocturnal enuresis: Minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).

Sublingual: Primary nocturnal enuresis (DDAVP Melt [Canadian product]): Tablet should be kept under the tongue until completely dissolved. Fluid restriction should be observed. Minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).

Parenteral:

Central diabetes insipidus: IV push or SubQ: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.

Hemophilia A and von Willebrand disease (type 1): IV infusion: Infuse over 15 to 30 minutes.

Storage/Stability

DDAVP:

Nasal spray: Store at 20°C to 25°C (68°F to 77°F). Keep nasal spray in upright position.

Rhinal Tube solution: Store at 2°C to 8°C (36°F to 46°F). May store at 20°C to 25°C (68°F to 77°F) for up to 3 weeks.

Solution for injection: Store at 2°C to 8°C (36°F to 46°F).

Tablet: Store at 20°C to 25°C (68°F to 77°F). Avoid excessive heat. Protect from light.

DDAVP Melt [Canadian product]: Store at 15°C to 25°C (59°F to 77°F) in original container. Protect from moisture.

Nocdurna: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture and light.

Noctiva: Store at 2°C to 8°C (36°F to 46°F); excursions permitted between 0°C and 15°C (32°F and 59°F). Keep nasal spray in upright position. After opening, store at 20°C to 25°C (68°F to 77°F). Discard 60 days after opening.

Octostim [Canadian product]:

Nasal spray: Store at 15°C to 25°C (59°F to 77°F). Store in upright position. Do not freeze.

Solution for injection: Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Following dilution in NS may store at room temperature for up to 24 hours.

Stimate nasal spray: Store at room temperature not to exceed 25°C (77°F). Discard 6 months after opening bottle. Store bottle in upright position.

Preparation for Administration: Adult

DDAVP injection: Hemophilia A and von Willebrand disease (type 1): Dilute solution for injection in 50 mL NS for IV infusion.

Octostim injection [Canadian product]: Dilute solution for injection in 50 mL NS for IV infusion.

Preparation for Administration: Pediatric

Parenteral: IV infusion: Dilute solution for injection in 10 to 50 mL NS; volume of diluent dependent on patient weight (Infants and children ≤10 kg: 10 mL; Children >10 kg and adolescents: 50 mL)

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to help prevent bedwetting.

• It is used to treat a health problem called nocturnal polyuria that causes you to have to wake up at night to pass urine.

• It is used to treat diabetes insipidus.

• It is used to treat hemophilia.

• It is used to treat von Willebrand disease.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Flushing

• Dry mouth

• Abdominal cramps

• Stuffy nose

• Runny nose

• Common cold symptoms

• Back pain

• Cough

• Nosebleed

• Sore throat

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Low sodium like headache, difficulty focusing, trouble with memory, confusion, weakness, seizures, or change in balance.

• Severe cerebrovascular disease like change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes.

• DVT like edema, warmth, numbness, change in color, or pain in the extremities.

• Nausea

• Vomiting

• Sensing things that seem real but are not

• Loss of strength and energy

• Agitation

• Muscle weakness

• Muscle spasms

• Excessive weight gain

• Lack of appetite

• Shortness of breath

• Severe headache

• Severe dizziness

• Passing out

• Vision changes

• Swelling of arms or legs

• Chest pain

• Coughing up blood

• Fast heartbeat

• Abnormal heartbeat

• Injection site pain, edema, or irritation

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Geriatric Patients: High-Risk Medication:

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Nocdurna sublingual tablets: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022517s000lbl.pdf#page=14

Contraindications

Known hypersensitivity to desmopressin or any component of the formulations; hyponatremia or a history of hyponatremia

Additional product specific contraindications:

DDAVP (injection, intranasal, oral): Moderate to severe renal impairment (CrCl <50 mL/minute)

Nocdurna, Noctiva: Renal impairment (eGFR <50 mL/minute/1.73 m2); polydipsia; primary nocturnal enuresis; concomitant use with loop diuretics or glucocorticoids (inhaled or systemic); syndrome of inappropriate antidiuretic hormone (SIADH) secretion (known or suspected); illnesses that may cause fluid or electrolyte imbalance (eg, gastroenteritis, salt-wasting nephropathies, systemic infection); heart failure (Noctiva labeling specifies NYHA Class II to IV); uncontrolled hypertension

Stimate: There are no contraindications listed in the Stimate prescribing information.

Canadian labeling: Additional contraindications (not in US labeling): Note: May not be applicable to all available dosage forms; refer to manufacturer labeling for further detail. Type 2B or platelet-type (pseudo) von Willebrand disease; habitual or psychogenic polydipsia, cardiac insufficiency or other conditions requiring diuretic therapy; nephrosis or any other condition associated with impaired water excretion, severe hepatic dysfunction; primary nocturnal enuresis; sodium losing conditions; SIADH secretion; lactose intolerance

Warnings/Precautions

Concerns related to adverse effects:

• Allergic reactions: Severe allergic reactions have been reported with desmopressin; anaphylactic reactions have only occurred rarely with IV and intranasal administration.

• Fluid retention: May cause fluid retention, which can worsen underlying conditions susceptible to volume status. Use with caution in patients with heart failure; some products are specifically contraindicated in heart failure or uncontrolled hypertension. Some products are not recommended in patients at risk for increased intracranial pressure or those with a history of urinary retention.

• Hyponatremia: [US Boxed Warning]: Nocdurna, Noctiva: Desmopressin can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death. Desmopressin is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. Ensure serum sodium concentrations are normal before starting or resuming desmopressin. Measure serum sodium within 7 days and ~1 month after initiating therapy or increasing the dose and periodically during treatment. More frequently monitor serum sodium in patients ≥65 years of age and in patients at increased risk of hyponatremia. If hyponatremia occurs, desmopressin may need to be temporarily or permanently discontinued. Desmopressin use may rarely lead to hyponatremia with associated signs and symptoms (eg, confusion, decreased consciousness, depressed reflexes, disorientation, fatigue, hallucinations, headache, irritability, lethargy, loss of appetite, muscle weakness/spasms/cramps, nausea/vomiting, restlessness, weight gain) and extreme decreases in plasma osmolality, resulting in seizures, coma, respiratory arrest, and death. Other risk factors for hyponatremia with desmopressin use include cystic fibrosis, renal impairment, heart failure, young age, advanced age, inappropriate high fluid intake, a higher than recommended dose, and concomitant use of medications known to either increase thirst or cause syndrome of inappropriate antidiuretic hormone secretion (SIADH). Fluid restriction during use is recommended. Fluid intake in the evening and nighttime hours should be moderated to decrease the risk of hyponatremia. Monitor for signs/symptoms of hyponatremia; more frequent monitoring is recommended for patients on concomitant medications that increase the risk of hyponatremia (eg, TCAs, SSRIs, NSAIDs, chlorpromazine, carbamazepine, thiazide diuretics).

• Hypotension: Severe hypotension may occur with rapid IV infusions.

• Thrombotic events: Acute cerebrovascular thrombosis and acute myocardial infarction have occurred (rare) with desmopressin injection; use with caution in patients predisposed to thrombus formation.

Disease-related concerns:

• Cardiovascular disease: Injection and high-dose intranasal (used in hemophilia A and von Willebrand disease) desmopressin may cause a slight increase or transient decrease in blood pressure, and a compensatory increase in heart rate. Use with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

• Polydipsia (habitual or psychogenic): Use with caution in patients with habitual or psychogenic polydipsia. Patients consuming excessive amounts of water are at greater risk of hyponatremia. Products used for the treatment of nocturia are specifically contraindicated in patients with polydipsia.

• Primary nocturnal enuresis: When using desmopressin for primary nocturnal enuresis, treatment should be interrupted if the patient experiences an acute illness (eg, fever, recurrent vomiting or diarrhea), vigorous exercise, or any condition associated with an increase in water consumption to prevent hyponatremia. Products used for the treatment of nocturia are specifically contraindicated in patients with primary nocturnal enuresis.

• von Willebrand disease type 2B: Patients with type 2B von Willebrand disease requiring hemostasis should not be treated with desmopressin since may result in platelet aggregation, thrombocytopenia, and possibly thrombosis.

Special populations:

• Elderly: Fluid intake should be adjusted downward in the elderly to decrease the possibility of water intoxication and hyponatremia.

• Pediatric: Fluid intake should be adjusted downward in very young patients to decrease the possibility of water intoxication and hyponatremia.

Dosage form specific issues:

• Intranasal: Consider alternative route of administration if changes in the nasal mucosa (scarring, edema) occur leading to unreliable absorption. Some patients may demonstrate a change in response after long-term therapy (>6 months) characterized as decreased response or a shorter duration of response. Discontinue in patients with concurrent nasal conditions that may increase systemic absorption of desmopressin (eg, acute or chronic rhinitis, severe atrophic rhinitis, nasal blockage, nasal mucosal atrophy, recent nasal surgery); may resume desmopressin when conditions resolve.

• Tablet: Consider alternative route of administration (IV or intranasal) with inadequate therapeutic response at maximum recommended oral doses.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Elderly patients should be cautioned not to increase their fluid intake beyond that sufficient to satisfy their thirst in order to avoid water intoxication and hyponatremia. Under experimental conditions, the elderly have been shown to have a decreased responsiveness to vasopressin with respect to its effects on water homeostasis.

Warnings: Additional Pediatric Considerations

The FDA has reviewed 61 postmarketing cases of hyponatremia-related seizures associated with the use of desmopressin acetate. Intranasal desmopressin was used in the majority of cases. Many of the patients were children being treated for primary nocturnal enuresis (PNE). An association with at least one concomitant drug or disease that also may cause hyponatremia and/or seizures was noted. As a result, intranasal desmopressin is no longer indicated for the treatment of PNE.

Pregnancy Considerations

In vitro studies demonstrate poor placental transfer of desmopressin.

Desmopressin may be used throughout pregnancy for the treatment of diabetes insipidus (Aleksandrov 2010; Ananthakrishnan 2016; Brewster 2005; Schrier 2010). Information related to desmopressin for the treatment of von Willebrand disease in pregnancy is limited (NHLBI 2007); however, use is recommended for bleeding prophylaxis when otherwise indicated (Demers 2018; Pacheco 2010; Trigg 2012). Desmopressin is not recommended for nocturia caused by normal physiologic changes which occur during pregnancy.

Breast-Feeding Considerations

Desmopressin is present in breast milk.

In a study conducted in 6 lactating women >4 months postpartum, breast milk concentrations of desmopressin were <1% of the maternal dose, collected over 8 hours following nasal administration. Analyses of milk from breastfeeding mothers receiving high-dose intranasal desmopressin indicate that the amount of desmopressin transferred to a breastfeeding child are considerably less than that required to influence diuresis.

Maternal use of desmopressin is not a contraindication to breastfeeding (Demers 2018). According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of infant exposure, benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Briggs' Drugs in Pregnancy & Lactation

• Desmopressin

Adverse Reactions

>10%:

Endocrine & metabolic: Hyponatremia (<1%; intranasal: 2% to 12%; sublingual: 3% to 4%)

Gastrointestinal: Xerostomia (sublingual: ≤14%)

1% to 10%:

Cardiovascular: Hypertension (intranasal: 2% to 3%)

Central nervous system: Headache (2% to 5%), dizziness (intranasal, sublingual: 2% to 3%), chills (intranasal: 2%), nostril pain (intranasal: 2%)

Gastrointestinal: Abdominal pain (intranasal: 2%), gastrointestinal disease (intranasal: 2%), nausea (intranasal: 2%)

Neuromuscular & skeletal: Asthenia (intranasal: 2%), back pain (intranasal: 1% to 2%)

Ophthalmic: Abnormal lacrimation (intranasal: 2%), conjunctivitis (intranasal: 2%), ocular edema (intranasal: 2%)

Respiratory: Rhinitis (intranasal: 3% to 8%), nasal discomfort (intranasal: 6%), nasopharyngitis (intranasal: 4%), nasal congestion (intranasal: ≤3%), epistaxis (intranasal: 2% to 3%), sneezing (intranasal: 2% to 3%), bronchitis (intranasal: 2%)

Frequency not defined:

Cardiovascular: Altered blood pressure, chest pain (intranasal), edema, facial flushing, flushing (intranasal), palpitations (intranasal), tachycardia (intranasal)

Central nervous system: Abnormality in thinking, agitation (intranasal), drowsiness (intranasal), insomnia (intranasal), localized warm feeling (intranasal), pain (intranasal)

Endocrine & metabolic: Weight gain

Gastrointestinal: Abdominal cramps, diarrhea, dyspepsia (intranasal), sore throat (intranasal), vomiting (intranasal)

Genitourinary: Balanitis (intranasal), vulvar pain

Hepatic: Increased serum aspartate aminotransferase (oral; transient)

Local: Burning sensation at injection site, erythema at injection site, swelling at injection site

Ophthalmic: Eye pruritus (intranasal), photophobia (intranasal)

Respiratory: Cough (intranasal), upper respiratory tract infection

<1%, postmarketing, and/or case reports: Anaphylaxis, atrial fibrillation, dysuria, serum hyposmolality, severe hypersensitivity, water intoxication

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Desmopressin Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

CarBAMazepine: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

ChlorproMAZINE: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Corticosteroids (Nasal): May enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Corticosteroids (Orally Inhaled): May enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Corticosteroids (Systemic): May enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Demeclocycline: May diminish the therapeutic effect of Desmopressin. Risk C: Monitor therapy

LamoTRIgine: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Lithium: May diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. Risk C: Monitor therapy

Loop Diuretics: May enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Loperamide-Loperamide Oxide: May increase the serum concentration of Desmopressin. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Opioid Agonists: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Tolvaptan: May diminish the therapeutic effect of Desmopressin. Risk X: Avoid combination

Tricyclic Antidepressants: May enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy

Monitoring Parameters

Blood pressure and pulse should be monitored during IV infusion

Note: For all indications, fluid intake, urine volume, and signs and symptoms of hyponatremia should be closely monitored especially in high-risk patient subgroups (eg, young children, elderly, patients with heart failure).

Diabetes insipidus: Urine specific gravity, plasma and urine osmolality, serum electrolytes

Hemophilia A: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII antigen levels, aPTT

von Willebrand disease: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand antigen levels, bleeding time

Nocturnal enuresis: Serum electrolytes if used for >7 days

Nocturia: Serum sodium concentrations at baseline, within 7 days, ~1 month after initiating/resuming therapy or increasing the dose, and periodically during therapy. More frequent monitoring in patients ≥65 years of age and those at increased risk of hyponatremia.

Uremic bleeding: Octostim [Canadian product]): Bleeding time before and 1 hour after IV infusion.

Advanced Practitioners Physical Assessment/Monitoring

Obtain fluid intake and urine volume in all patients. Obtain urine specific gravity, plasma and urine osmolality, and serum electrolytes in patients with diabetes insipidius. In patients with hemophilia A, obtain Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII antigen levels, and aPTT. Obtain Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand antigen levels, and bleeding time in patients with von Willebrand disease. In patients with nocturnal enuresis using for >7 days obtain serum electrolytes. Monitor blood pressure and pulse during IV infusion. Monitor for signs and symptoms of hyponatremia.

Nursing Physical Assessment/Monitoring

Check ordered labs and report abnormalities. Monitor for signs of hypersensitivity reaction. Monitor for signs of hyponatremia (nausea, vomiting, headache, irritability, muscle weakness, muscle cramps) and instruct patient to report any signs or symptoms. Educate patient on importance of restricting fluids during therapy.

Dosage Forms Considerations

DDAVP and Minirin 5 mL bottles contain 50 sprays.

Stimate 2.5 mL bottles contain 25 sprays.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Emulsion, Nasal, as acetate:

Noctiva: 0.83 mcg/0.1 mL (3.8 g [DSC]); 1.66 mcg/0.1 mL (3.8 g)

Solution, Injection, as acetate:

DDAVP: 4 mcg/mL (1 mL)

DDAVP: 4 mcg/mL (10 mL) [contains chlorobutanol (chlorobutol)]

Generic: 4 mcg/mL (1 mL, 10 mL)

Solution, Injection, as acetate [preservative free]:

Generic: 4 mcg/mL (1 mL)

Solution, Nasal, as acetate:

DDAVP: 0.01% (5 mL) [contains benzalkonium chloride]

DDAVP Rhinal Tube: 0.01% (2.5 mL) [contains chlorobutanol (chlorobutol)]

Stimate: 1.5 mg/mL (2.5 mL) [contains benzalkonium chloride]

Generic: 0.01% (2.5 mL [DSC], 5 mL)

Tablet, Oral, as acetate:

DDAVP: 0.1 mg

DDAVP: 0.2 mg [scored]

Generic: 0.1 mg, 0.2 mg

Tablet Sublingual, Sublingual:

Nocdurna: 27.7 mcg, 55.3 mcg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection:

Octostim: 15 mcg/mL (1 mL)

Solution, Injection, as acetate:

DDAVP: 4 mcg/mL (1 mL)

Solution, Nasal, as acetate:

DDAVP: 0.01% (2.5 mL, 5 mL) [contains benzalkonium chloride]

DDAVP Rhinyle: 0.01% (2.5 mL, 5 mL) [contains chlorobutanol (chlorobutol)]

Octostim: 1.5 mg/mL (2.5 mL) [contains chlorobutanol hemihydrate]

Generic: 0.01% (2.5 mL, 5 mL)

Tablet, Oral, as acetate:

DDAVP: 0.1 mg, 0.2 mg

Generic: 0.1 mg, 0.2 mg

Tablet Disintegrating, Sublingual:

DDAVP Melt: 60 mcg, 120 mcg, 240 mcg

Nocdurna: 25 mcg, 50 mcg

Anatomic Therapeutic Chemical (ATC) Classification

• H01BA02

Generic Available (US)

May be product dependent

Pricing: US

Emulsion (Noctiva Nasal)

1.66 mcg/0.1 mL (per gram): $134.21

Solution (DDAVP Injection)

4 mcg/mL (per mL): $97.37

Solution (DDAVP Nasal)

0.01% (per mL): $114.20

Solution (DDAVP Rhinal Tube Nasal)

0.01% (per mL): $132.41

Solution (Desmopressin Ace Spray Refrig Nasal)

0.01% (per mL): $49.25

Solution (Desmopressin Acetate Injection)

4 mcg/mL (per mL): $12.34 - $71.42

Solution (Desmopressin Acetate Spray Nasal)

0.01% (per mL): $47.28 - $49.25

Solution (Stimate Nasal)

1.5 mg/mL (per mL): $351.36

Sublingual (Nocdurna Sublingual)

27.7 mcg (per each): $16.80

55.3 mcg (per each): $16.80

Tablets (DDAVP Oral)

0.1 mg (per each): $9.35

0.2 mg (per each): $13.47

Tablets (Desmopressin Acetate Oral)

0.1 mg (per each): $1.26 - $7.36

0.2 mg (per each): $1.41 - $10.60

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Synthetic analogue of the antidiuretic hormone arginine vasopressin. In a dose dependent manner, desmopressin increases cyclic adenosine monophosphate (cAMP) in renal tubular cells which increases water permeability resulting in decreased urine volume and increased urine osmolality; increases plasma levels of von Willebrand factor, factor VIII, and t-PA contributing to a shortened activated partial thromboplastin time (aPTT) and bleeding time.

Pharmacodynamics/Kinetics

Onset of action:

Intranasal: Antidiuretic: 15 to 30 minutes; Increased factor VIII and von Willebrand factor (vWF) activity (dose related): 30 minutes

Peak effect: Antidiuretic: 1 hour; Increased factor VIII and vWF activity: 1.5 hours; Nocturia: 0.25 to 0.75 hour

IV infusion: Increased factor VIII and vWF activity: 30 minutes (dose related)

Peak effect: 1.5 to 2 hours

Oral tablet: Antidiuretic: ~1 hour

Peak effect: 4 to 7 hours

Sublingual: Antidiuretic: ~30 minutes

Duration: Intranasal, Injection, Oral tablet, Sublingual: ~6 to 14 hours

Absorption: Sublingual: Rapid

Bioavailability: Intranasal: ~3.5%; Oral tablet: 5% compared to intranasal, 0.16% compared to IV; Sublingual: 0.25%

Half-life elimination: 2 to 4 hours; Severe renal impairment: ~9 hours

Excretion: Urine (primarily)

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: AUC and T1/2 are ~3- to 4-fold higher in patients with eGFR <50 mL/minute/1.73 m2.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Frequent occurrence of xerostomia (normal salivary flow resumes upon discontinuance) with sublingual application has been reported.

Effects on Bleeding

Rare reports of thrombotic events including thromboembolism have been associated with desmopressin, although no causality has been determined.

Related Information

• Beers Criteria 2019: Potentially Inappropriate Medication Use in Older Adults ≥65 Years of Age
• Oral Medications That Should Not Be Crushed or Altered

Pharmacotherapy Pearls

10 mcg of desmopressin acetate is equivalent to 40 units

Index Terms

1-Deamino-8-D-Arginine Vasopressin; Desmopressin Acetate

FDA Approval Date

February 21, 1978

References

2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767[PubMed 30693946]

Aleksandrov N, Audibert F, Bedard MJ, Mahone M, Goffinet F, Kadoch IJ. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can. 2010;32(3):225-231.[PubMed 20500966]

Ananthakrishnan S. Diabetes insipidus during pregnancy. Best Pract Res Clin Endocrinol Metab. 2016;30(2):305-315. doi: 10.1016/j.beem.2016.02.005.[PubMed 27156766]

Asplund R and Aberg H, "Desmopressin in Elderly Subjects With Increased Nocturnal Diuresis: A Two-Month Treatment Study," Scand J Urol Nephrol, 1993, 27(1):77-82.[PubMed 8493474]

Brewster UC and Hayslett JP, "Diabetes Insipidus in the Third Trimester of Pregnancy," Obstet Gynecol, 2005, 105(5 Pt 2):1173-6.[PubMed 15863571]

Byrnes JJ, Larcada A, and Moake JL, "Thrombosis Following Desmopressin for Uremic Bleeding," Am J Hematol, 1988, 28(1):63-5.[PubMed 3259400]

Cattaneo M, "Review of Clinical Experience of Desmopressin in Patients With Congenital and Acquired Bleeding Disorder," Eur J Anesthesiol Suppl, 1997, 14:10-4.

Cheetham T and Baylis PH, "Diabetes Insipidus in Children," Pediatr Drugs, 2002, 4(12):785-96.[PubMed 12431131]

Chistolini A, Dragoni F, Ferrari A, et al, "Intranasal DDAVP®: Biological and Clinical Evaluation in Mild Factor VIII Deficiency," Haemostasis, 1991, 21(5):273-7.[PubMed 1806455]

Couch P and Stumpf JL, "Management of Uremic Bleeding," Clin Pharm, 1990, 9(9):673-81.[PubMed 2171866]

Das P, Carcao M, and Hitzler J, "DDAVP-Induced Hyponatremia in Young Children," J Pediatr Hematol Oncol, 2005, 27(6):330-2.[PubMed 15956888]

Das P, Carcao M, and Hitzler J, "Use of Recombinant Factor VIIa Prior to Lumbar Puncture in Pediatric Patients With Acute Leukemia," Pediatr Blood Cancer, 2006, 47(2):206-9.[PubMed 16007583]

Dave SP, Greenstein AJ, Sachar DB, et al, "Bleeding Diathesis in Amyloidosis With Renal Insufficiency Associated With Crohn's Disease: Response to Desmopressin," Am J Gastroenterol, 2002, 97(1):187-9.[PubMed 11808946]

DDAVP Injection (desmopressin) injection [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; March 2018.

DDAVP Injection (desmopressin) injection [product monograph]. North York, Ontario, Canada: Ferring; April 2017.

DDAVP Melt (desmopressin) orally disintegrating tablets [product monograph]. North York, Ontario: Ferring; September 2018.

DDAVP Nasal Spray (desmopressin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; September 2018.

DDAVP Rhinal Tube (desmopressin) spray [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; April 2015.

DDAVP Spray and DDAVP Rhinyl (desmopressin) [product monograph]. North York, Ontario: Ferring; April 2018.

DDAVP Tablets (desmopressin) tablet [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; December 2014.

DDAVP Tablets (desmopressin) [product monograph]. North York, Ontario: Ferring; December 2015.

Demers C, Derzko C, David M, Douglas J. No. 163-Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders. J Obstet Gynaecol Can. 2018;40(2):e91-e103. doi: 10.1016/j.jogc.2017.11.036.[PubMed 29447730]

Eller N, Kollenz CJ, and Hitzenberger G, "A Comparative Study of Pharmacodynamics and Bioavailability of 2 Different Desmopressin Nasal Sprays," Int J Clin Pharmacol Ther, 1998, 36(3):139-45.[PubMed 9562229]

Eller N, Kollenz, Bauer P, et al, "The Duration of Antidiuretic Response of Two Desmopressin Nasal Sprays," Int J Clin Pharmacol Ther, 1998, 36(9):494-500.[PubMed 9760011]

Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016; 24(1):6-46.[PubMed 26714677]

Lusher JM, "Response to 1-Deamino-8-D-Arginine Vasopressin in von Willebrand Disease," Haemostasis, 1994, 24(5):276-84.[PubMed 7843638]

MacMillan TE, Tang T, Cavalcanti RB. Desmopressin to prevent rapid sodium correction in severe hyponatremia: a systematic review. Am J Med. 2015;128(12):1362.e15-24. doi: 10.1016/j.amjmed.2015.04.040.[PubMed 26031887]

Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356(22):2301-2311.[PubMed 17538089]

Mannucci PM and Cattaneo M, "Desmopressin: A Nontransfusional Treatment of Hemophilia and von Willebrand Disease," Haemostasis, 1992, 22(5)276-80.

Mannucci PM, Remuzzi G, Pusineri F, et al, "Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia," N Engl J Med, 1983, 308(1):8-12.[PubMed 6401193]

Molnar Z, Farkas V, Nemes L, et al, "Hyponatraemic Seizures Resulting From Inadequate Post-Operative Fluid Intake Following a Single Dose of Desmopressin," Nephrol Dial Transplant, 2005, 20(10):2265-7.[PubMed 16014348]

National Heart, Lung, and Blood Institute, “The Diagnosis, Evaluation, and Management of von Willebrand Disease,” NIH Publication No. 08-5832. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood, 2007.

Nocdurna (desmopressin acetate) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; June 2018.

Nocdurna (desmopressin) [product monograph]. North York, Ontario, Canada: Ferring Inc; September 2014.

Noctiva (desmopressin) [prescribing information]. Chesterfield, MO: Avadel Specialty Pharmaceuticals LLC; December 2017.

Octostim (desmopressin) [product monograph]. North York, Ontario, Canada: Ferring Inc; April 2018.

Pacheco LD, Costantine MM, Saade GR, Mucowski S, Hankins GD, Sciscione AC. Von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment. Am J Obstet Gynecol. 2010;203(3):194-200. doi: 10.1016/j.ajog.2010.02.036.[PubMed 20417473]

Rembratt A, Graugaard-Jensen C, Senderovitz T, et al, "Pharmacokinetics and Pharmacodynamics of Desmopressin Administered Orally Versus Intravenously at Daytime Versus Night-Time in Healthy Men Aged 55-70 Years," Eur J Clin Pharmacol, 2004, 60(6):397-402.[PubMed 15197520]

Rembratt A, Riis A, and Norgaard JP, "Desmopressin Treatment in Nocturia; An Analysis of Risk Factors for Hyponatremia," Neurourol Urodyn, 2005, 25(2):105-9.[PubMed 16304673]

Richardson DW and Robinson AG, "Desmopressin," Ann Intern Med, 1985, 103(2):228-39.[PubMed 3893256]

Robson WL, Leung AK, and Norgaard JP, "The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children With Nocturnal Enuresis," J Urol, 2007, 178(1):24-30.[PubMed 17574054]

Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf). 1998;48(2):235-241.[PubMed 9579238]

Schrier RW, "Systemic Arterial Vasodilation, Vasopressin, and Vasopressinase in Pregnancy," J Am Soc Nephrol, 2010, 21(4):570-2.[PubMed 19959721]

Smith TJ, Gill JC, Ambruso DR, et al, "Hyponatremia and Seizures in Young Children given DDAVP," Am J Hematol, 1989, 31(3):199-202.[PubMed 2500851]

Sood L, Sterns RH, Hix JK, Silver SM, Chen L. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia. Am J Kidney Dis. 2013;61(4):571-578. doi: 10.1053/j.ajkd.2012.11.032.[PubMed 23266328]

Stenberg A and Läckgren G, "Desmopressin Tablets in the Treatment of Severe Nocturnal Enuresis in Adolescents," Pediatrics, 1994, 94(6 Pt 1):841-46.[PubMed 7970999]

Sterns RH. Overview of the treatment of hyponatremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2018.

Stimate (desmopressin acetate) nasal spray [prescribing information]. King of Prussia, PA: CSL Behring; June 2013.

Thumfart J, Roehr CC, Kapelari K, et al, "Desmopressin Associated Symptomatic Hyponatremic Hypervolemia in Children. Are There Predictive Factors?" J Urol, 2005, 174(1):294-8.[PubMed 15947670]

Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012;18(1):25-33. doi: 10.1111/j.1365-2516.2011.02573.x.[PubMed 21624012]

Watson AJ and Keogh JA., "1-Deamino-8-D-Arginine Vasopressin as a Therapy for the Bleeding Diathesis of Renal Failure," Am J Nephrol, 1984a, 4(1):49-51.[PubMed 6731500]

Watson AJ and Keogh JA, "1-Deamino-8-d-Arginine Vasopressin (DDAVP): A Potential New Treatment for the Bleeding Diathesis of Acute Renal Failure," Pharmatherapeutica, 1984, 3(9):618-22.[PubMed 6728864]

Weinstein RE, Bona RD, Altman AJ, et al, "Severe Hyponatremia after Repeated Intravenous Administration of Desmopressin," Am J Hematol, 1989, 32(4):258-61.[PubMed 2816922]

Brand Names: International

Adin (NZ); Adiupressin (UA); Adiuretin SD (HU); Adiuretin-SD (CZ, PL); D-VOID (IN); DDAVP (BR, CL, IT); DDAVP Desmopressin (PT); Defirin (GR); Demolavus (EG); Denirin (KR); Des-Press (LK); Desmin (KR); Desmogalen (DE); Desmomelt (BE, GB); Desmop ODIFS Powder (KR); Desmopresin DDAVP (AR); Desmospray (GB, IE, PT); Desmotab (GB, IE); Desmotabs (DE); Desonic (KR); Deturine (KR); Dinadom (AR); Egypress (EG); Minirin (AT, AU, BG, CH, CN, CO, CR, DE, DK, DO, EC, EE, EG, FI, FR, GT, HN, HR, HU, ID, IL, IS, KR, LK, LT, LU, LV, MY, NI, NO, NZ, PA, PE, PH, PK, PT, PY, RO, RU, SE, SG, SK, SV, TR, TW, UA); Minirin DDAVP (AE, BH, CY, GR, HK, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, TH, YE); Minirin Melt (AE, AU, CR, CU, CY, DO, EG, GT, HN, IL, KW, LB, NI, PA, PH, QA, SA, SV, TH); Minirin Nasal Spray (AU, NZ); Minirinmelt (FR); Minirinmelt OD (JP); Minrin (BE, LU, NL); Minurin (ES); Nafiset (MX); Nocdurna (AT, AU, CZ, DE, DK, HK, HR, HU, IS, LB, NO, PT, RO, SG, SK); Noctisson (AE, BG, IQ, IR, JO, LY, OM, SY, YE); Nocutil (AT, CH, DK); Nocutil Nasenspray (DE); Noqdirna (MT); Noqturina (EE); Octim (FR); Octim Nasal Spray (GB); Octostim (AE, AR, AT, AU, BH, CH, CL, CO, CR, DE, DO, EC, EE, ES, FI, GT, HK, HN, HU, IL, IQ, IR, IS, KW, LT, LV, LY, MX, NI, NL, NO, NZ, OM, PA, QA, SE, SG, SV, SY, UA, YE); Octostim Nasal Spray (KR); Octostin (AR); Ovea Odifs Powder (KR); Pizzard (MX); Presinex (BG, GB); Uremin (KR)

Last Updated 3/21/20